DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced an investor update presentation will be available at 9:00 a.m....
Company recognized for its innovative contributions to the life sciences industry in North Carolina DURHAM, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today...
HAV performance in the clinical setting as an arteriovenous reconstruction underscores the potential for use as vascular access conduits for dialysis patients DURHAM, N.C., May 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally...
Laboratory and pre-clinical models of whole-lung engineering inform roadmap for building a functional lung alveolus, which is the key building block for making a functional lung Data presented at 38th Annual Meeting of the Japanese Association for Chest Surgery DURHAM, N.C., May 21, 2021 (GLOBE...
Proven CFO with extensive financial leadership and commercialization experience, including multiple publicly listed life sciences companies DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered...
DURHAM, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that clinical investigators and senior leadership will present at five scientific and...
Five-year outcomes demonstrate HAV retained durability and structural integrity, potentially offering a safe and viable option for long-term hemodialysis Long-term explant samples demonstrate progressive host cell remodeling to create living vascular tissue; no indication of rejection of HAV ...
DURHAM, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50...
DURHAM, N.C., March 23, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Rajiv Shukla, Alpha...
DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human...
